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ABSTRACT 
Background: Epilepsy is a chronic disorder that typically requires lifelong 
pharmacologic treatment. The choice of an antiepileptic drug (AED), therefore, 
requires careful consideration of efficacy and tolerability. However, the major- 
ity of patients with new-onset seizures are initially treated by physicians in the 
emergency department (ED) or by non-ED physicians (primary care physicians 
or internists), with phenytoin being the most common AED prescribed for ini- 
tial therapy, and the long-term adverse ffects of AEDs are often overlooked. 
Objective: The aim of this survey was to examine the perspectives of neu- 
rologists and epileptologists concerning initial therapies prescribed by ED physi- 
cians and non-ED physicians for newly diagnosed partial seizures, particularly 
phenytoin, and the suitability of these therapies for long-term management of 
the disease. 
Methods: A computerized survey was conducted during the 2004 American 
Academy of Neurology meeting. The survey consisted of 10 questions concern- 
ing the use of AEDs in the initial and long-term treatment of newly diagnosed 
partial seizures. 
Results" The responses of 268 practitioners were analyzed. Survey partici- 
pants indicated that 71% of patients referred to them by ED physicians were 
receiving phenytoin, whereas 59% of patients referred to them by non-ED physi- 
cians were receiving phenytoin. Seventy-six percent o[ survey participants 
responded that they would switch a patient having partial seizures referred 
from the ED to another AED. Seventy-eight percent indicated that they did not 
believe that the medications being received by patients with newly diagnosed 
partial seizures in the ED were suitable for long-term epilepsy treatment. 
Conclusion: Although appropriate treatment might vary in the acute and 
chronic settings, and phenytoin is used as a primary agent [or acute treatment 
of seizures presenting inthe ED, the results of the present survey suggest adis- 
crepancy between the medications that primary care and ED physicians pre- 
scribe for newly diagnosed partial seizures and those that specialists prescribe 
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for long-term therapy. (Curt Ther Res Clin Exp. 2005;66:255-265) Copyright © 
2005 Excerpta Medica, Inc. 
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INTRODUCTION 
The chronic nature of epilepsy requires long-term treatment. The adverse 
effects associated with the long-term use of antiepileptic drugs (AEDs) thus 
present an important consideration i the choice of treatment. Adverse effects 
associated with AEDs occur in more than half of patients who use them, 1 with 
the long-term adverse ffects often being overlooked) 
The majority of patients with new-onset seizures are initially treated by 
physicians in the emergency department (ED) or by non-ED physicians (pri- 
mary care physicians or internists), with phenytoin being the most common 
AED prescribed for initial therapy. 3,4 Phenytoin is one of the few AEDs available 
in both an intravenous formulation for use during emergencies, and an oral for- 
mulation for use alter an intravenous loading dose. 5 In addition, together with 
phenobarbital nd valproic acid, phenytoin is among only a handful of IV agents 
approved by the US Food and Drug Administration lor initial monotherapy for 
epilepsy and is the most commonly used AED in North America. 6
Although phenytoin is used as a primary agent for acute treatment of sei- 
zures, its selection as a long-term treatment lor epilepsy is receiving increas- 
ing attention and debate. In 2001, an epilepsy consensus panel guideline was 
published. 7 It listed carbamazepine first, and then phenytoin, as potential first- 
line therapies for both simple and complex partial seizures. The consensus also 
indicated that when carbamazepine is the first agent prescribed for a patient 
with partial seizures, and that therapy fails, the next agents that should be tried 
are lamotrigine, phenytoin, and valproic acid, in that order. On the other hand, 
if the first monotherapy regimen that was tried and failed was phenytoin, then 
the next agents that should be tried are carbamazepine, lamotrigine, and oxcar- 
bazepine. Nonetheless, it can be said that both carbamazepine and phenytoin 
are effective acute treatments of complex partial seizures. However, long-term 
use of phenytoin, and potentially carbamazepine, could be problematic. 
Cosmetic adverse effects, including gingival hyperplasia, acne, hirsutism, 
and facial coarsening, are associated with long-term phenytoin use. s-u Neu- 
ropathy and cerebellar atrophy might also occur. 9,12 In addition, the association 
of long-term phenytoin use with altered bone metabolism and low bone miner- 
al density (BMD) has emerged as an important issue. Prolonged AED use was 
associated with bone disease in the 1960s, 13 with the bulk of available data 
relating to traditional AEDs, such as phenytoin, phenobarbital, carbamazepine, 
and valproic acid. 14 However, this adverse ffect associated with long-term use 
is often overlooked; a survey of neurologists found that only 28% of adult neu- 
rologists indicated that they routinely evaluate AED-treated patients for bone 
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and mineral disease, and <10% indicated that they prescribe prophylactic al- 
cium and vitamin D. 15 
An important concern with long-term phenytoin use is its association with bone 
disorders, the most serious forms of which are osteopenia/osteoporosis, osteoma- 
lacia, and fractures. 16 Carbamazepine has also been associated with bone disease 
because, like phenytoin, it is a hepatic enzyme inducer. However, in a review of 
studies of the effects of carbamazepine use on bone and mineral metabolism and 
BMD, Pack and Morrel117 found conflicting results, with some studies showing a 
correlation with altered bone metabolism and turnover, and other studies how- 
ing no abnormalities. In addition, although hepatic induction of the cytochrome 
P450 (CYP) system leading to increased catabolism of vitamin D has been the 
mechanism most frequently reported as the link between AEDs and bone dis- 
ease, 18,19 non-vitamin D-mediated mechanisms of action of AEDs on bone have 
also been proposed. A review of the literature concerning AEDs and BMD found 
substantial indirect evidence that the negative ffects of AEDs on BMD occur by a 
variety of mechanisms--impaired calcium absorption, increased bone turnover, 
interference with vitamin K metabolism, inhibition of osteocalcin, and increased 
urinary loss of calcium and phosphorus due to renal tubular dysfunction--and 
that an increased rate of bone turnover might be the most significant osteopenic 
effect of AEDs. 14 
To examine the perspectives of neurologists and epileptologists concerning 
therapies initially prescribed by ED and non-ED physicians to treat newly diag- 
nosed partial seizures and the likelihood that these therapies would also be 
used in the long-term management of the disease, with a focus on phenytoin, a
survey (Appendix) was conducted at the 2004 American Academy of Neurology 
(AAN) meeting. 
MATERIALS AND METHODS 
A computerized survey was conducted at an exhibit booth during the 2004 AAN 
meeting in San Francisco, California. The survey consisted of 10 questions con- 
cerning the prescription of AEDs in the initial and long-term treatment of newly 
diagnosed partial seizures. Only the responses of physicians, osteopathic 
physicians, nurse-practitioners, and physicians' assistants from the United 
States who indicated their specialty as being epileptology, neurology, or pedi- 
atric neurology were used for analysis. 
The survey was completed by a random sample of people who visited the 
booth, all of unknown relation to the pharmaceutical personnel attending the 
booth at the meeting. One query concerned the total number of patients with 
partial seizures they treated per month. Survey participants were also queried 
about their preferred therapies for newly diagnosed partial seizures and which 
AEDs that patients referred from ED or non-ED physicians are most likely receiv- 
ing. For these questions, survey participants were asked to choose from a list 
of drugs, including extended-release (ER) carbamazepine, immediate-release (IR) 
257 
CURRENT THERAPEUTIC RESEARCH 
carbamazepine, oxcarbazepine, phenytoin, valproic acid, and other agents (eg, 
gabapentin, lamotrigine, levetiracetam, topiramate). In addition, survey partici- 
pants were asked specifically about phenytoin, including how many referred 
patients with newly diagnosed partial seizures are receiving it, and whether 
they believe it is an appropriate long-term therapy for these patients. 
RESULTS 
Demographic Characteristics 
The demographic characteristics of the survey participants are shown in the 
table. Of 541 practitioners who participated in the survey, 334 were from the 
United States, the majority (90%) of whom were physicians (88% MDs, 2% DOs). 
Most (87%) of the US participants also indicated their specialty as being neurology 
or epileptology. After exclusion criteria were applied, survey participants otaled 
268. Twenty-nine percent of neurologists and epileptologists surveyed indicated 
Table. Demographic characteristics of the survey participants. 
No. (°/6) 
Characteristic of Participants 
US participants (n = 334) 
Highest academic degree 
MD 294 (88) 
DO 7 (2) 
Other* 33 (I 0) 
Specialty 
Neurology/epileptology 291 (87) 
Other 43 (13) 
Participants included in the analysis (n = 268) 
No. of patients with seizure seen each month 
<-10 77 (29) 
11-25 86 (32) 
26-.50 .S9 (22) 
>so 46 (17) 
Practice setting 
Hospital 131 (49) 
Private practice 70 (26) 
Group practice 24 (9) 
Outpatient clinic 21 (8) 
Inpatient clinic 3 (1) 
Other 19 (7) 
MD = doctor of medicine; DO = doctor of osteopathy. 
*Includes nurse-practitioner and physician's assistant. 
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that they see ___10 patients with seizures per month; 32%, 11 to 25 patients; 22%, 
26 to 50 patients; and 17%, >50 patients. Nearly half of survey participants (49%) 
indicated that they practice in a hospital setting. 
In i t ia l  T reatment  of  Newly  Diagnosed Part ia l  Seizures 
Sixty-six percent of survey participants indicated that their top choice for 
treating newly diagnosed partial seizures is carbamazepine (Figure 1). The 
question did not specify acute or long-term treatment. Forty-four percent chose 
carbamazepine-ER as their preferred therapy; and 22%, carbamazepine-IR. 
Fourteen percent chose oxcarbazepine; 9%, phenytoin; 3%, valproic acid; and 
8%, other AEDs. However, survey participants indicated that only 13% of patients 
referred by ED physicians are receiving carbamazepine-IR and that 8% are 
receiving carbamazepine-ER. Based on the survey results, of patients who were 
referred by non-ED physicians, 19% are receiving carbamazepine-lR; and 12%, 
carbamazepine-ER. 
Phenytoin 
Specialists reported that 71% of patients referred by ED physicians were receiv- 
ing phenytoin, whereas 59% of patients referred by non-ED physicians were receiv- 
ing it. However, 76% of survey participants indicated that they would switch a 
patient with partial seizures referred from an ED from phenytoin to another AED 
(69% would switch them to carbamazepine; 22%, to carbamazepine-IR; and 47%, 
to carbamazepine-ER). 
Of the 64 (24%) survey participants who would not switch therapies, 31 (12%) 
indicated that hey would not switch therapies because they believe that phenytoin 
8% 5% 
[] Carbamazepine-ER 
[] Carbarnazepine-IR 
[]  Oxcarbazepine 
[]  Phenytoin 
[]  Valproate 
[]  Other agents 
14% 
44% 
Figure 1. Specialists' (N = 268) top choices for initial therapies for newly diagnosed 
partial seizures. ER = extended release; IR = immediate release. 
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is an appropriate long-term therapy (Figure 2). Seventeen (6%) would not switch 
because of convenience; 14(5%), because of cost concerns; and 11 (4%), because 
of the concern about breakthrough seizures or effects of seizures. Five (2%) indi- 
cated that they were unclear about how to switch a patient to another AED. 
Long-Term Treatment of Newly Diagnosed Partial Seizures 
Seventy-eight percent of survey participants indicated that they did not 
believe that the medication received by patients with newly diagnosed par- 
tial seizures in the ED is suitable for the long-term treatment of epilepsy. 
Sixty-seven percent said that they frequently switch patients from phenytoin 
to another AED using titration. In addition, 51% of survey participants said 
they regularly and 28% occasionally discuss AEDs with referring ED physi- 
cians; 53% regularly and 34% occasionally discuss AEDs with referring non-ED 
physicians. 
DISCUSSION 
The majority of neurologists and epileptologists surveyed indicated that they 
believe that the initial therapies used for newly diagnosed partial seizures are 
inappropriate for the long-term anagement of the disease. In particular, most 
would switch patients who had been prescribed initial therapy with phenytoin 
in the ED to another AED, with carbamazepine b ing their top choice for treat- 
10 
8 
6 
4 
2 
0 
12 
Figure 2. 
m 
// // 
T r T - ~  
Appropriate Convenience Cost Concern Unsure of 
Long-Term Regarding How to 
Therapy Breakthrough Switch 
Seizures 
Reasons for not switching patients with partial seizures referred by emer- 
gency department physicians from phenytoin to another antiepileptic drug 
(n = 78). 
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ing newly diagnosed partial seizures. Even among the specialists who indicated 
that they would not switch a patient from phenytoin, less than half believed 
that phenytoin is an appropriate long-term therapy. However, in many coun- 
tries, phenytoin might be the only practical approach due to limited availabil- 
ity and cost of other long-term treatment options. The need to have patients 
with new-onset partial seizures adequately and rapidly treated with an AED 
intravenously oaded to a therapeutic range prior to discharge from the ED 
might be a major factor in deciding on the appropriate treatment option. Al- 
though an agent used in the ED might be appropriate for short-term care, it 
might not be the patient's best option over the long term. 
The results of this survey suggest that there is a discrepancy between the med- 
ications that primary care and ED physicians prescribe for newly diagnosed partial 
seizures and those that specialists prescribe for long-term therapy. Itmust be con- 
sidered, however, that appropriate herapy for epilepsy might differ in the short 
and long terms in individual patients requiring medical intervention. Because the 
survey participants did not include primary care physicians, it could be assumed 
that the majority of these physicians would not change drug therapy for long-term 
management because they had not at the time of referral. This assumption is impor- 
tant because the diagnosis and management of epilepsy are routinely performed by 
primary care physicians. Inthe United States, only 17% of patients with new-onset 
epilepsy are examined by neurologists for their ongoing care. 4
This study was limited by its small sample size. The results might have been 
biased by the number and types of choices provided in the questions and the 
environment in which the survey was completed (pharmaceutical company 
booth). The study is also limited by the characteristics (type of practice, num- 
ber of patients with seizure treated, exposure to literature, continuing medical 
education, and pharmaceutical company education on various AEDs and side- 
effect profiles) of the practitioners who completed the instrument, and the 
recall bias of the survey completers. 
CONCLUSION 
Although appropriate treatment might vary in the acute and chronic settings, 
the results of the present survey suggest a discrepancy between the medica- 
tions that primary care and ED physicians prescribe for acute treatment of 
newly diagnosed partial seizures and those that specialists prescribe for long- 
term therapy. 
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Appendix. Antiepileptic Drug Survey. 
You are about to participate in a marketing survey for Epilepsy and other product specific 
questions. This survey is for US health care providers only. 
First Name: 
Last Name: 
MD DO PA NP 
Other 
Specialty: (These specialties are offered in a pull-down menu.) 
__  Psychiatry 
__  Neurology 
__  Primary Care (FP, GP, IM) 
__  Pediatrics 
__  Other 
Type of setting that you see the majority of your patients (Select ONE): 
__  Private Practice 
__  Hospital Practice 
__  Group Practice 
__  Out patient 
__  In patient clinic 
__  Other 
Would you be interested in participating in similar Shire US Inc. or other e-Council TM 
programs via e-mail in the future? 
Yes No 
E-mail Address: 
Office, Hospital, Institution or Business Name: 
Address: City: State: ___  Zip: . . . .  
Please note that Shire may use your personal information to contact you for future mar- 
keting initiatives. Information from this survey will not be leased, sold, or distributed to 
third parties by Shire or its representatives. 
1. What is the total number of partial seizure patients you treat in your practice per 
month? 
a. Less than 10 
b. 11-25 
c. 26-50 
d. More than 50 
2. When choosing a product for your newly diagnosed partial seizure patients, please 
rank your top three choices from the list below. 
(Participant will check one for each) 
First choice: a b c d e f 
Second choice: a b c d e f 
(continued) 
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Appendix. (Continued) 
Third choice: a b c d e f 
a. Extended-release carbamazepine 
b. Immediate-release carbamazepine 
c. Oxcarbazepine 
d. Phenytoin 
e. Valproic acid 
f. Other agents 
3. When new partial seizure patients are referred to you from Emergency Room physi- 
cians, which of the following medications are they most likely to be taking? 
Most likely: a b c d e f 
Second most likely: a b c d e f 
Third most likely: a b c d e f 
a. Extended-release carbamazepine 
b. Immediate-release carbamazepine 
c. Oxcarbazepine 
d. Phenytoin 
e. Valproic acid 
f. Other agents 
4. When new partial seizure patients are referred to you from NON-Emergency Room 
physicians (eg, PCPs, Internists) which of the following medications are they most 
likely to be taking? 
Most likely: a b c d e f 
Second most likely: a b c d e f 
Third most likely: a b c d e f 
a. Extended-release carbamazepine 
b. Immediate-release carbamazepine 
c. Oxcarbazepine 
d. Phenytoin 
e. Valproic acid 
f. Other agents 
5. What is the average length of time between when a patient is put on an 
Antiepileptic Drug for partial seizures in the Emergency Room until you first see 
them? 
a. I 0 days or less 
b. More than I 0 days but less than I month 
c. I month 
d. 2-4 months 
e. 5 months or more 
(continued) 
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Appendix. (Continued) 
6. For epilepsy patients that are initially treated in an Emergency Room, do you gener- 
ally feel that the medication received there is also suitable for the long-term manage- 
ment of their epilepsy? 
a. Yes 
b. No 
7. If a partial seizure patient came to you after initiating therapy on Phenytoin in the 
Emergency Room, would you choose a different treatment option? 
a. Yes 
b. No 
If yes, which ONE would you prescribe to them? (Note to programmer-allow for one 
choice only) 
a. Extended-release carbamazepine 
b. Immediate-release carbamazepine 
c. Oxcarbazepine 
d. Valproic acid 
e. Other agents 
If no, what is it that prevents you from using a new treatment option? Select all that 
apply. 
a. Fear of breakthrough seizures or side effects from seizures 
b. Phenytoin is an appropriate long-term therapy 
c. Unclear how to switch to other antiepileptic drugs when on a stable dose of 
phenytoin 
d. Convenience 
e. Cost 
8. How often do you discuss antiepileptic drug medications with referring emergency 
room physicians? 
a. Regularly 
b. Occasionally 
c. Rarely 
d. Never 
9. How often do you discuss antiepileptic drug medications with referring NON- 
emergency room physicians? 
a. Regularly 
b. Occasionally 
c. Rarely 
d. Never 
10. How would you rate your level of experience in titrating patients off of phenytoin 
and on to another antiepileptic drug? 
a. Very experienced/frequently do this 
b. Some experience 
c. Not very experienced/rarely do this 
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